RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer
NCT ID: NCT02502656
Last Updated: 2016-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
425 participants
OBSERVATIONAL
2015-07-31
2017-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No prior chemotherapy with the exception of adjuvant chemotherapy completed ≥ 6 months prior to enrollment
* Signed written informed consent obtained prior to any study specific screening procedures
* Patients willing to provide a blood sample for Translational Research
Exclusion Criteria
* Previous malignancy in the last 5 years
* Medical, sociological, psychological or legal conditions that would not permit the patient to sign informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Association des Gastroentérologues Oncologues
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Baptiste Bachet, Dr
Role: PRINCIPAL_INVESTIGATOR
Association des Gastro-entérologues Oncologues (AGEO)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Avicenne
Bobigny, , France
Hopital Béclère
Clamart, , France
Hopital Henri Mondor
Créteil, , France
Hopital Kremlin-Bicêtre
Le Kremlin-Bicêtre, , France
CH Longjumeau et Sud
Longjumeau, , France
Hopital Mermoz
Lyon, , France
Hopital Cochin
Paris, , France
Hopital Saint-Antoine
Paris, , France
Hopital Saint-Louis
Paris, , France
Hôpital Européen Georges Pompidou
Paris, , France
Hôpital Pitié Salpêtrière
Paris, , France
CHU Poitiers
Poitiers, , France
CHU Robert Debré
Reims, , France
Hôpital Trousseau
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Thomas Aparicio, Pr
Role: primary
L Marthey, Dr
Role: primary
Christophe Tournigand, Pr
Role: primary
Anne Thirot- Bidault, Dr
Role: primary
J Ezenfis, Dr
Role: primary
Gérard Lledo, Dr
Role: primary
Romain Coriat, Pr
Role: primary
Thierry André, Pr
Role: primary
Jean-Marc Gornet, Dr
Role: primary
Julien Taieb, Pr
Role: primary
Jean-Baptiste Bachet, Dr
Role: primary
David Tougeron, Pr
Role: primary
Olivier Bouché, Pr
Role: primary
Thierry Lecomte, Pr
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Bachet JB, Laurent-Puig P, Meurisse A, Bouche O, Mas L, Taly V, Cohen R, Gornet JM, Artru P, Louafi S, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Blons H, Vernerey D, Taieb J. Circulating tumour DNA at baseline for individualised prognostication in patients with chemotherapy-naive metastatic colorectal cancer. An AGEO prospective study. Eur J Cancer. 2023 Aug;189:112934. doi: 10.1016/j.ejca.2023.05.022. Epub 2023 Jun 7.
Bachet JB, Bouche O, Taieb J, Dubreuil O, Garcia ML, Meurisse A, Normand C, Gornet JM, Artru P, Louafi S, Bonnetain F, Thirot-Bidault A, Baumgaertner I, Coriat R, Tougeron D, Lecomte T, Mary F, Aparicio T, Marthey L, Taly V, Blons H, Vernerey D, Laurent-Puig P. RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study. Ann Oncol. 2018 May 1;29(5):1211-1219. doi: 10.1093/annonc/mdy061.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RASANC
Identifier Type: -
Identifier Source: org_study_id